Brian Armstrong Invests $130 Million in Anti-Aging Startup NewLimit

Coinbase CEO Brian Armstrong is taking on two major challenges: the complexities of human aging and the evolving landscape of cryptocurrency regulation. He’s tackling these issues head-on by investing in his biotechnology venture, NewLimit. This $130 million Series B funding round brings NewLimit’s valuation to a staggering $810 million. The startup aims to reverse the effects of aging through epigenetic reprogramming, targeting liver cells as its initial focus point for improving alcohol and fat metabolism. Early lab results are promising, but human trials remain years away. 💰🔬